Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma

Puey Ling Chia, Prudence A Russell, Andrew M Scott, Thomas John

Research output: Contribution to journalReview ArticleResearchpeer-review

5 Citations (Scopus)

Abstract

Introduction: Malignant mesothelioma (MM) is an aggressive malignancy of the pleura and other serosal membranes originating from mesothelial cells that, despite decades of research, continues to have limited therapeutic options and is associated with a poor prognosis. Areas covered: MMs induce a strong inflammatory response that is also associated with neoangiogenesis and activation of proangiogenic factors. Given this, several anti-angiogenic agents have been trialled in a variety of malignancies including mesothelioma. Herein we summarise the role of angiogenesis in MM and the current available data targeting these pathways. Expert commentary: The addition of bevacizumab to cisplatin/pemetrexed chemotherapy is currently a therapeutic option with a proven 2.7 month overall survival benefit in fit patients less than 75. Other antiangiogenics such as nintedinib show early promise, although the Phase III trial results are eagerly awaited before this therapy enters treatment paradigms. Beyond this, it is likely that combinations of antiangiogenics with immunotherapies will be investigated in future studies.

Original languageEnglish
Pages (from-to)1235-1245
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume16
Issue number12
DOIs
Publication statusPublished - Dec 2016
Externally publishedYes

Keywords

  • angiogenesis
  • anti-angiogenic agents
  • Mesothelioma
  • tumour microenvironment
  • vascular endothelial growth factor

Cite this